Simulation-based design of pragmatic trials in psoriatic arthritis using propensity scores

Simulation-based design of pragmatic trials in psoriatic arthritis using propensity scores

Design of clinical trials requires careful decision-making across several dimensions, including endpoints, eligibility criteria, and subgroup enrichment. Clinical trial simulation can be an informative tool in trial design, providing empirical evidence by which to evaluate and compare the results of...

Bibliografski detalji
Glavni autori:	Weinstein, SM, Coates, LC, Helliwell, PS, Ogdie, A, Stephens-Shields, AJ
Format:	Journal article
Jezik:	English
Izdano:	SAGE Publications 2021

Slični predmeti

Psoriatic arthritis: prospects for the future
od: Hackett, S, i dr.
Izdano: (2022)

Measuring outcomes in psoriatic arthritis
od: Ogdie, A, i dr.
Izdano: (2020)

THE DIAGNOSIS OF PSORIATIC ARTHRITIS
od: P.S. Helliwell
Izdano: (2011-09-01)

Impact of clinical domains other than arthritis on composite outcomes in psoriatic arthritis: comparison of treatment effects in the SEAM-PsA trial
od: Helliwell, PS, i dr.
Izdano: (2022)

What should be the primary target of "treat to target" in psoriatic arthritis?
od: Coates, LC, i dr.
Izdano: (2018)

Psoriatic arthritis: prospects for the future
od: Simon Hackett, i dr.
Izdano: (2022-03-01)

Psoriatic arthritis
od: FitzGerald, O, i dr.
Izdano: (2021)

Comparing the visual analogue scale and the numerical rating scale in patient-reported outcomes in psoriatic arthritis
od: Ye, W, i dr.
Izdano: (2021)

Inhibition of interleukin-17 in patients with oligoarticular psoriatic arthritis
od: Ogdie, A, i dr.
Izdano: (2023)

The role of ultrasound in psoriatic arthritis — do we need a score?
od: D'Agostino, MA, i dr.
Izdano: (2019)

Comparative performance of composite measures from two phase III clinical trials of ixekizumab in psoriatic arthritis
od: Coates, LC, i dr.
Izdano: (2022)

Measuring physical function in psoriatic arthritis: comparing the Multi-Dimensional Health Assessment Questionnaire to the Health Assessment Questionnaire Disability Index
od: Ye, W, i dr.
Izdano: (2021)

Current concepts and unmet needs in psoriatic arthritis
od: Mahmood, F, i dr.
Izdano: (2017)

Long-term follow-up of patients in the TIght COntrol of inflammation in early Psoriatic Arthritis (TICOPA) trial
od: Coates, L, i dr.
Izdano: (2019)

Evaluation and validation of a patient completed psoriatic arthritis flare questionnaire
od: Helliwell, PS, i dr.
Izdano: (2021)

Performance of composite measures used in a trial of etanercept and methotrexate as monotherapy or in combination in psoriatic arthritis
od: Coates, L, i dr.
Izdano: (2020)

Psoriasis, psoriatic arthritis, and rheumatoid arthritis: Is all inflammation the same?
od: Coates, L, i dr.
Izdano: (2016)

Outcome measures in psoriatic arthritis: where next?
od: Hackett, S, i dr.
Izdano: (2022)

Validity and score interpretation of the 12-item Psoriatic Arthritis Impact of Disease: an analysis of pooled data from two phase 3 trials of bimekizumab in patients with psoriatic arthritis
od: Laure Gossec, i dr.
Izdano: (2024-02-01)

Assessing disease activity in psoriatic arthritis: a literature review
od: Tucker, L, i dr.
Izdano: (2018)

The comparative performance of three screening questionnaires for psoriatic arthritis in a primary care surveillance study
od: Helliwell, PS, i dr.
Izdano: (2023)

Time to response for clinical and patient-reported outcomes in patients with psoriatic arthritis treated with tofacitinib, adalimumab, or placebo
od: Gladman, DD, i dr.
Izdano: (2022)

Classification and outcome measures for psoriatic arthritis
od: Leung, Y, i dr.
Izdano: (2018)

Hot topice debate: preventing psoriatic arthritis in patients with psoriasis
od: Vivekanantham, A, i dr.
Izdano: (2024)

Sex-specific differences in patients with psoriatic arthritis: a systematic review
od: Coates, LC, i dr.
Izdano: (2022)

Clinical trial discrimination of physical function instruments for psoriatic arthritis: A systematic review
od: Leung, Y-Y, i dr.
Izdano: (2020)

Outcomes of the 2019 GRAPPA workshop on continuous composite indices for the assessment of psoriatic arthritis and membership: Recommended next steps
od: Tillett, W, i dr.
Izdano: (2020)

How should we define disease and outcomes in axial psoriatic arthritis?
od: Coates, LC
Izdano: (2021)

Identification of psoriatic arthritis in patients with psoriasis
od: Coates, LC, i dr.
Izdano: (2023)

GRAPPA 2021 treatment recommendations for psoriatic arthritis
od: Soriano, ER, i dr.
Izdano: (2023)

The State of the Art - Psoriatic Arthritis outcome assessment in clinical trials and daily practice
od: Day, J, i dr.
Izdano: (2022)

New GRAPPA recommendations for the management of psoriasis and psoriatic arthritis: process, challenges and implementation
od: Coates, L, i dr.
Izdano: (2016)

Impact of clinical domains other than arthritis on composite outcomes in psoriatic arthritis: comparison of treatment effects in the SEAM-PsA trial
od: Atul Deodhar, i dr.
Izdano: (2022-07-01)

Psoriatic Arthritis: A Review
od: Farrouq Mahmood, i dr.
Izdano: (2016-07-01)

Obesity and Psoriatic Arthritis: A Narrative Review
od: Anand Kumthekar, i dr.
Izdano: (2020-06-01)

Classification and Outcome Measures for Psoriatic Arthritis
od: Ying Ying Leung, i dr.
Izdano: (2018-09-01)

Inhibition of Interleukin-17 in Patients with Oligoarticular Psoriatic Arthritis
od: Alexis Ogdie, i dr.
Izdano: (2023-05-01)

Psoriatic arthritis in developing and resource-poor countries
od: Maharaj, AB, i dr.
Izdano: (2020)

Methotrexate in psoriasis and psoriatic arthritis
od: Coates, L, i dr.
Izdano: (2020)

GRAPPA-OMERACT initiative to standardise outcomes in psoriatic arthritis clinical trials and longitudinal observational studies
od: Tillett, W, i dr.
Izdano: (2017)